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Letters to the Editors ajog.orgThe conventional APS treatment including aspirin and
low-molecular-weight heparin combination is effective in
approximately 70% of pregnancies that are improved using
this regimen, but almost 30% of patients (refractory APS) are
still unable to give birth to healthy neonates despite this
conventional treatment. In the abovementioned PREGNancy
in women with ANTiphospholipid Syndrome study, the
authors discussed several additional treatments for refractory
APS, including corticosteroids, plasma exchange, and intra-
venous immunoglobulins.
However, it is surprising that hydroxychloroquine (HCQ)
was not cited in the study by Saccone et al.1
Currently HCQ is an important additional treatment for
refractory APS,2-4 acting in antithrombotic activities, and as
an antiinﬂammatory agent, reducing the antiphospholipid
antibody (aPL) bindings to syncytiotrophoblasts, restoring
annexin A5 expression, and antagonizing the aPL mediate
inhibition of trophoblast migration, invasion, and
differentiation.
In addition, the inhibition of lysosomal enzymatic
function is hypothesized to be one of the causes of HCQ
beneﬁcial effects. HCQ inhibits the lysosomal degradation
of mucopolysaccharides and proteins by inhibiting major
histocompatibility complex class IIedependent antigen
processing and presentation by monocytes. This process
decreases the antigen binding to the surface of the pro-
fessional antigen-presenting cells, reducing the number of
peptide-major histocompatibility complex class II com-
plexes for transport to the cell surface and presentation to
CD4 T cells. Moreover, HCQ inhibits the interaction of
memory B cells, but not unprimed B cells speciﬁc for
foreign antigens, and modulates some steps in the synthesis
and metabolism of interleukin-1. Both these mechanisms
result in the inhibition of the generation of
immunoglobulin-secreting cells. Therefore, there are 2
consequences of these mechanisms: the reduction in pro-
duction of autoantibodies and the nonactivation of the
complement system.
HCQ has been shown to have an important role to
improve pregnancy outcome4 and to reduce the anti-
phospholipid antibodies title.2
In conclusion, we aim to highlight the importance of the
use of HCQ as additional treatment in patients with
refractory APS. For the future, the beneﬁcial effect of HCQ in
high-risk-proﬁle APS patients, as women showing triple aPL
positivity, or in the treatment of APS will be clariﬁed by
further studies. -
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PREGNancy in women with ANTiphospholipid Syndrome
(PREGNANTS) study.1 PREGNANTS is a multicenter
cohort study of women with primary antiphospholipid
syndrome (APS) referred to 7 Italian university hospitals.
Strict inclusion criteria were used. Only women treated with
both low-dose aspirin and prophylactic low-molecular-
weight heparin (LMWH) were included. Those who
received other therapies, including hydroxychloroquine,
were intentionally excluded to provide a homogenous
study group.
The best treatment of women with APS is still a subject of
debate, and several therapies have been studied.2 Treatment
with hydroxychloroquine has been evaluated in a
few observational nonrandomized studies, and the observa-
tions suggest that this therapy may improve pregnancy out-
comes beyond that observed with LMWH and aspirin.
However, because the efﬁcacy in singleton gestations with
primary APS and without systemic lupus erythematosus
has not been proved in an appropriately powered randomized
trial,3 its use is not currently recommended by guidelines.1
In the PREGNANTS study, of the 1201 primary APS
pregnant women screened for the inclusion criteria, 19
(1.6%) were excluded because they also received other ther-
apies. This means that clinicians feel uncomfortable using
other therapies4 if not recommended by international
guidelines2 and if efﬁcacy is not supported by level 1 data.
We fully support randomized controlled trials of
ajog.org Letters to the Editorshydroxychloroquine for the treatment of APS in pregnancy in
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